Welcome! Things are moving fast... It's been a busy summer at Serva. We attended conferences across the country connecting with policymakers and technologists around nuclear innovation. It's been amazing to see the significant advances underway in nuclear technology, and I've enjoyed meeting the people behind the technology too. I’m happy to report that we’ve made major progress on a couple of projects, including developing much-needed medical isotopes like Actinium-225 (Ac225) that can be used as part of a powerful antibody therapy treatment for cancer patients. (Check out the before-and-after Ac225 image below that shows its cancer-curing abilities.) The issue with Ac225 has always been low production, and we’ve got the technology that can solve this problem—the same technology that will bring in a new age of safe and cost-effective nuclear fuels through our Smart Nuclear Materials. Our advancements in Ac225 production not only serve the greater patient population, but coincide with our fuel goals allowing for expedited development of both. Stay tuned for more news on the nuclear medicine front, as we continue down this road. (Because we don't want to just solve the energy crisis, we want to cure cancer also!) Cheers,
Ian |
|
|
Image showing advanced stage cancer in remission after just three doses of Actinium-225 (Ac225) antibody therapy. |
|
|
American Nuclear Society (ANS) Winter Meeting and Technology Expo |
|
|
Our paper on FPGA driven ADCs for resolution restoration of pre-amplifier signal and deconvolution strategies was accepted for presenting at the ANS Winter conference this November. This paper on our new digital technologies illustrates how bringing in modern PCBs (Printed Circuit Boards) will have a dramatic impact on lab measurements for us and the greater scientific community as a whole. It will also improve these old designs by greatly simplifying the hardware systems so much so that we can run an entire commercial nuclear reactor on a single desktop computer while improving safety, reliability and cost. Ian Horvath
Chief Executive Officer |
|
|
Dr. Jones was a featured speaker at US Women in Nuclear (WIN) National Conference |
|
|
Last month in Richmond, Virginia, Dr. Sarah Jones, Vice President for Serva Medical, presented on Serva's work with medical isotopes and their impact in the detection and treatment of diseases, including cancer, as a featured speaker at the U.S. Women in Nuclear (WIN) National Conference, led by the Nuclear Energy Institute (NEI). Dr. Jones led the “Nuclear Medicine: Innovation in Developing Radioisotopes” panel, which explored how "advanced data mining, artificial intelligence, and data analytics can drive insights and identify pathways to create needed isotopes including a novel production method for Actinium 225.” The panel, facilitated by Grace Watters, a Nuclear Chemistry Technician at Millstone Power Station—Dominion Energy, examined the “70 plus years since radioactive iodine was first used to treat thyroid cancer” and how the field of nuclear medicine “has expanded to include the use of over 45 radioisotopes fostering advances in imaging and the treatment of cancer and other diseases. Progress, however, has been restricted due to chronic supply chain challenges and limitations in availability of key isotopes.” |
|
|
Support for Serva is growing: Transcending our fundraising goal |
|
|
Our last round of fundraising exceeded expectations. Within two weeks, we had commitments for the fully subscribed $3 million with additional offers of over-subscriptions in the millions that we are contemplating for the next round of funding. This will allow us to hire more key people, attend and present at more conferences, further our testing at reactors and universities, and expand our technology in numerous verticals. Greg Anderson
Chief Operating Officer |
|
|
A new chapter for Serva: Introducing Serva Medical |
|
|
Serva’s same innovative technologies that are driving our development of a new generation of Smart Nuclear Materials can be applied with great effect in nuclear medicine using radioactive substances to diagnose, evaluate and treat diseases. Nuclear medicine has expanded to include more than 45 radioisotopes used in advanced imaging and radiotherapy. The potential growth in this field to expand both the treatment options and the different radioisotopes remains immense. “Serva is poised to be a significant disruptor in health care, as our proprietary technology is not only able to identify new and better pathways to developing currently used medical radioisotopes, our technology is able to identify other life-saving isotopes as well,” said Dr. Sarah Jones, Vice President for Serva Medical. “Applying our software technology, the Isotope Searcher, we are able to identify all possible pathways for the development of all medical isotopes that could be used to treat cancer and other life-threatening diseases.” More updates on Serva Medical are coming soon, but in the meantime you can learn about our collaboration with Arizona State University and the Mayo Clinic this past spring. Serva Energy selected for Mayo Clinic, ASU MedTech Accelerator In the news: 'Tempe company paves the way in nuclear medicine' |
|
|
|
|
